Ongoing Research Seeks to Optimize Targeted Therapy Use in mCRC - OncLive
Targeted therapies for metastatic colorectal cancer (mCRC) are moving to earlier treatment lines, emphasizing the importance of molecular testing. Key options include anti-EGFR therapy for RAS wild-type patients, BRAF V600E inhibitors like encorafenib, and HER2-directed therapies such as trastuzumab plus tucatinib. Ongoing trials aim to integrate these therapies into first-line settings, including MOUNTAINEER-03 for HER2-positive patients and studies on new RAS-targeted therapies.
Related Clinical Trials
Highlighted Terms
Related News
Targeted therapies for metastatic colorectal cancer (mCRC) are moving to earlier treatment lines, emphasizing the importance of molecular testing. Key options include anti-EGFR therapy for RAS wild-type patients, BRAF V600E inhibitors like encorafenib, and HER2-directed therapies such as trastuzumab plus tucatinib. Ongoing trials aim to integrate these therapies into first-line settings, including MOUNTAINEER-03 for HER2-positive patients and studies on new RAS-targeted therapies.